1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. Apoptosis | 凋亡
  5. Apoptosis

Vincristine-d3-ester sulfate (Leurocristine-d3-ester (sulfate); NSC-67574-d3-ester (sulfate); 22-Oxovincaleukoblastine-d3-ester (sulfate))

别名: [2H3]-长春新碱硫酸盐; 硫酸长春新碱 ester (硫酸盐)
目录号: V52538 纯度: ≥98%
COA 产品数据 产品说明书 SDS
长春新碱-d3-酯（硫酸盐）是硫酸长春新碱的氘代形式。
Vincristine-d3-ester sulfate (Leurocristine-d3-ester (sulfate); NSC-67574-d3-ester (sulfate); 22-Oxovincaleukoblastine-d3-ester (sulfate)) CAS号: 1217854-24-4
产品类别: Apoptosis
产品仅用于科学研究，不针对患者销售
规格 价格 库存 数量
1mg
Other Sizes
加入购物车 结帐 大包装询价
020-31522723 sales@invivochem.cn

Other Forms of Vincristine-d3-ester sulfate (Leurocristine-d3-ester (sulfate); NSC-67574-d3-ester (sulfate); 22-Oxovincaleukoblastine-d3-ester (sulfate)):

  • 硫酸长春新碱
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
产品描述
长春新碱-d3-酯（硫酸盐）是硫酸长春新碱的氘代形式。硫酸长春新碱是一种抗肿瘤长春花生物碱，可以抑制有丝分裂纺锤体中微管的形成，导致分裂细胞在中期停滞。其微管结合的 Ki 为 85 nM。
生物活性&实验参考方法
体外研究 (In Vitro)
药物化合物包括碳、氢和其他元素的稳定重同位素，在药物开发过程中主要作为定量示踪剂。由于氘化可能会影响药物的药代动力学和代谢特性，因此值得关注[1]。
参考文献

[1]. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7.

[3]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87.

[4]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7.

[5]. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000.

[6]. Baguley, B.C. et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7.

[7]. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108.
其他信息
Vincristine Sulfate can cause developmental toxicity according to state or federal government labeling requirements.
Vincristine sulfate appears as an anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5. (NTP, 1992)
Vincristine Sulfate is the sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C46H58N4O14S
分子量
923.036132335663
CAS号
1217854-24-4
相关CAS号
Vincristine sulfate;2068-78-2
PubChem CID
21864436
外观&性状
White to off-white solid powder
熔点
531 °F approximately (NTP, 1992)
氢键供体(HBD)数目
5
氢键受体(HBA)数目
16
可旋转键数目(RBC)
10
重原子数目
65
分子复杂度/Complexity
1830
定义原子立体中心数目
0
SMILES
S(O)(O)(=O)=O.C([C@]12C=CCN3CC[C@@]4(C5=CC([C@]6(C[C@@]7([H])C[C@@](O)(CC)C[N@@](CCC8C9=CC=CC=C9NC6=8)C7)C(=O)OC([H])([H])[H])=C(OC)C=C5N(C=O)[C@@]4([H])[C@@](O)(C(=O)OC)[C@@H]1OC(=O)C)[C@]23[H])C
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意： (1). 本产品在运输和储存过程中需避光。  (2). 请将本产品存放在密封且受保护的环境中（例如氮气保护），避免吸湿/受潮。
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)
注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。
注射用配方
(IP/IV/IM/SC等)
注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。
View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。
View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。
请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 1.0834 mL 5.4169 mL 10.8338 mL
5 mM 0.2167 mL 1.0834 mL 2.1668 mL
10 mM 0.1083 mL 0.5417 mL 1.0834 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
CTID: NCT05675410
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
CTID: NCT04759586
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
CTID: NCT02723994
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-29
Treatment of Acute Lymphoblastic Leukemia in Children
CTID: NCT00400946
Phase: Phase 3    Status: Completed
Date: 2024-11-27
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Mantle Cell Lymphoma
CTID: NCT03710772
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-27
View More

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
CTID: NCT04799275
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-11-27

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
CTID: NCT04530565
Phase: Phase 3    Status: Recruiting
Date: 2024-11-25
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
CTID: NCT03871257
Phase: Phase 3    Status: Recruiting
Date: 2024-11-22
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
CTID: NCT02877303
Phase: Phase 2    Status: Recruiting
Date: 2024-11-20
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
CTID: NCT04166409
Phase: Phase 3    Status: Recruiting
Date: 2024-11-19
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
CTID: NCT00792948
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
CTID: NCT02166463
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
CTID: NCT02112916
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
CTID: NCT02883049
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
CTID: NCT02101853
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
CTID: NCT01856192
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
CTID: NCT00972478
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
CTID: NCT03269669
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-12
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
CTID: NCT03984448
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-11-12
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
CTID: NCT03220022
Phase: Phase 1    Status: Recruiting
Date: 2024-11-12
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
CTID: NCT04994132
Phase: Phase 3    Status: Recruiting
Date: 2024-11-08
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
CTID: NCT03504644
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-11-06
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
CTID: NCT00085735
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-05
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
CTID: NCT03749018
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-04
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
CTID: NCT00077285
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-04
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
CTID: NCT04850495
Phase: Phase 1    Status: Recruiting
Date: 2024-10-31
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
CTID: NCT04546399
Phase: Phase 2    Status: Suspended
Date: 2024-10-30
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
CTID: NCT03126916
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-26
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
CTID: NCT05157971
Phase: Phase 1    Status: Recruiting
Date: 2024-10-26
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
CTID: NCT03150693
Phase: Phase 3    Status: Suspended
Date: 2024-10-26
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
CTID: NCT02724579
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-26
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
CTID: NCT02143414
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-23
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
CTID: NCT03959085
Phase: Phase 3    Status: Recruiting
Date: 2024-10-22
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
CTID: NCT00554788
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-22
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
CTID: NCT05761171
Phase: Phase 2    Status: Recruiting
Date: 2024-10-22
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
CTID: NCT03914625
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-21
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
CTID: NCT00980460
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-21
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
CTID: NCT00408005
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-21
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
CTID: NCT03007147
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-18
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
CTID: NCT04139304
PhaseEarly Phase 1    Status: Active, not recruiting
Date: 2024-10-16
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
CTID: NCT03533582
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-15
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
CTID: NCT02567435
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-01
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
CTID: NCT00336024
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-01
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
CTID: NCT00004112
Phase: Phase 3    Status: Completed
Date: 2024-09-23
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ('EPOCH') for Adult T-Cell Leukemia-Lymphoma (ATL)
CTID: NCT04301076
Phase: Phase 1    Status: Recruiting
Date: 2024-09-20
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
CTID: NCT00392327
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-09-19
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
CTID: NCT01231906
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-09-19
Parsaclisib Plus the Standard Drug Therapy in Patients with Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
CTID: NCT04323956
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-09-19
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
CTID: NCT00107198
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-09-19
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
CTID: NCT03505762
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-09-19
Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
CTID: NCT00501826
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
CTID: NCT02306161
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-09-05
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
CTID: NCT00670358
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-08-29
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
CTID: NCT02828358
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-09
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
CTID: NCT03488225
Phase: Phase 2    Status: Terminated
Date: 2024-07-16
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
CTID: NCT01798004
Phase: Phase 1    Status: Completed
Date: 2024-07-15
Combination Chemotherapy With
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
CTID: null
Phase: Phase 2    Status: Trial now transitioned, Ongoing
Date: 2021-07-30
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.
CTID: null
Phase: Phase 3    Status: Trial now transitioned, Ongoing
Date: 2020-11-30
Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma
CTID: null
Phase: Phase 2    Status: GB - no longer in EU/EEA
Date: 2020-07-06
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667).
CTID: null
Phase: Phase 2    Status: Trial now transitioned, GB - no longer in EU/EEA
Date: 2019-06-14
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric
CTID: null
Phase: Phase 2    Status: Ongoing, Completed
Date: 2019-03-04
STELLAR: A phase II, randomiSed study of CHOP-R in combination with acalabruTinib comparEd to CHOP-R in patients with newLy diagnosed Richter’s Syndrome (RS) and a pLAtfoRm for initial investigations into activity of novel treatments in relapsed/refractory and newly diagnosed RS.
CTID: null
Phase: Phase 2    Status: GB - no longer in EU/EEA
Date: 2019-01-31
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH
CTID: null
Phase: Phase 3    Status: Completed, Trial now transitioned, GB - no longer in EU/EEA, Ongoing
Date: 2018-08-31
A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard therapy.
CTID: null
Phase: Phase 1    Status: Ongoing, Completed
Date: 2018-01-15
Paediatric Hepatic International Tumour Trial
CTID: null
Phase: Phase 3    Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2017-04-28
Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)
CTID: null
Phase: Phase 2    Status: GB - no longer in EU/EEA
Date: 2016-09-23
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-06-28
A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) or RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) as front-line therapy in patients with diffuse large B-cell lymphoma (DLBCL)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2016-04-05
A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO [GS-9973]) combined with Vincristine (VCR) in Adult Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2016-02-03
Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma
CTID: null
Phase: Phase 2, Phase 3    Status: Trial now transitioned, GB - no longer in EU/EEA
Date: 2015-09-30
Vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia: comparing one-hour infusions with short-term infusions (the VINCA-study)
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-08-25
ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMAS: A PHASE I-II STUDY.
CTID: null
Phase: Phase 1, Phase 2    Status: Ongoing
Date: 2014-05-27
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2014-03-07
Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2014-01-14
A PHASE III MULTICENTER, RANDOMIZED STUDY COMPARING CONSOLIDATION WITH (90)YTTRIUM-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) RADIOIMMUNOTHERAPY VS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA (FL) AGED 18-65 YEARS
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2013-10-08
Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing’s sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2013-10-07
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas
CTID: null
Phase: Phase 3    Status: Completed
Date: 2013-02-18
International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours
CTID: null
Phase: Phase 3    Status: Ongoing, GB - no longer in EU/EEA
Date: 2013-02-01
R-CHOP-14 or R-CHOP-21 & consolidation PET–oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients with low risk profile according to age-adjusted IPI (0 with bulky or 1)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-09-27
Reinduction protocol for patients with high-risk neuroblastoma in first relapse
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2012-09-20
A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Lymphoma
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2012-08-21
DIAGNOSTIC AND THERAPEUTIC STUDY FOR NEWLY DIAGNOSED RETINOBLASTOMA PATIENTS RTB AIEOP 012
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2012-02-14
United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011
CTID: null
Phase: Phase 3    Status: Ongoing, GB - no longer in EU/EEA
Date: 2011-12-02
Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal vincristine and FDG-PET based reduction of therapy in combination with vitamin D substitution
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-10-10
Phase II trial on safety and activity of intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt's lymphoma.
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2011-10-03
A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA
Date: 2010-12-20
ACNS0331
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2010-04-14
Traitement adjuvant dans les rétinoblastomes unilatéraux étendus énucléés d’emblée.
CTID: null
Phase: Phase 2    Status: Trial now transitioned
Date: 2009-12-15
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-12-04
Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukaemia (ALL)- MARALL
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2009-08-10
Phase ll study evaluating the toxicity and efficacy of a modified German Paediatric Hodgkin's Lymphoma protocol (HD95) in young adults (aged 18-30 years) with Hodgkin's Lymphoma
CTID: null
Phase: Phase 2    Status: Completed
Date: 2008-07-11
A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-04-29
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2008-04-25
A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia Chemotherapy
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2007-11-21
Feasibility study of R-CHOP plus bevacizumab in patients with diffuse large B cell lymphoma (DLBCL)
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2007-03-02
Use of mieloablative doses of zevalin in aggressive lymphomas of the elderly. Prospective randomized study Z-HDS1,2 vs R-CHOP
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2006-09-20
Etude multicentrique randomisée de phase III en ouvert comparant l'association Velcade Dexamethasone à la chimiothérapie de type VAD pour le traitement des patients porteurs de myélome multiple de novo jusqu'à l'âge de 65 ans
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-07-04
Cooperative multicentre study for children and adolescents with low grade glioma
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2006-05-03
Phase III multicentric IIL study, three randomized arms (R-CVP vs R-CHOP vs R-FM),for treatment of patients with stage II-IV follicular lymphoma
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-01-30
PROTOCOL OF DIAGNOSIS AND THERAPY FOR RETINOBLASTOMA - AIEOP RB 05
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2006-01-01
A phase II GISL study of R-HyperCVAD in the treatment of patients with Mantle cell Lymphoma
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-09-06
Pilotstudie zur Therapieoptimierungsstudie für den
CTID: null
Phase: Phase 4    Status: Completed
Date: 2005-05-19
MULTI-CENTRE, RANDOMISED, PHASE III TRIAL COMPARING HIGH DOSE SEQUENTIAL CHEMOTHERAPY hds WITH RITUXIMAB AND AUTOLOGOUS PERIPHERAL BLOOD PROGENITUR ALL TRANSPLANTION VERSUS 2- WEEKLY CHOP WITH RITUXIMAB AS FRONT LINE THERAPY OF HIGH RISK PATIENT WITH DIFFUSE LARGE B- CELL NON HODGKIN LYMPHOMA
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-04-12
A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and Rituximab
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-02-24
Evaluation of the intensification of post-remissional therapy in the treatment of high-risks adult Acute Lymphoblastic Leukemia and monitoring of the minimal residual disease
CTID: null
Phase: Phase 3    Status: Completed
Date: 2004-11-08
IntReALL HR 2010
CTID: null
Phase: Phase 2    Status: Trial now transitioned, Ongoing, Prematurely Ended
Date:

相关产品
联系我们
电话: 020-31522723 QQ： 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member